Page last updated: 2024-11-04

benzylsuccinic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Benzylsuccinic acid is a dicarboxylic acid that has been studied for its potential therapeutic applications. It is a key intermediate in the synthesis of various pharmaceutically active compounds, such as anticonvulsants and anti-inflammatory drugs. Research has focused on its synthesis using different methods, including the reaction of benzyl chloride with succinic anhydride and the use of a palladium-catalyzed coupling reaction. The compound has shown anti-inflammatory effects in animal models, suggesting its potential for treating inflammatory diseases. Additionally, it has been investigated for its role in inhibiting the growth of certain cancer cell lines. Benzylsuccinic acid is also a valuable starting material for the synthesis of other important organic compounds, contributing to its ongoing research interest.'

benzylsuccinic acid: inhibitor of carboxypeptidase A [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-benzylsuccinic acid : A dicarboxylic acid consisting of succinic acid carrying a 2-benzyl substituent. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3858
CHEMBL ID151284
CHEBI ID16054
SCHEMBL ID393002
MeSH IDM0040318

Synonyms (58)

Synonym
CBMICRO_015697
beta-carboxybenzenebutanoic acid
2-benzylsuccinic acid
alpha-benzylsuccinic acid
benzylsuccinic acid
2-benzylbutanedioic acid
(phenylmethyl)butanedioic acid
CHEBI:16054 ,
benzenebutanoic acid, .beta.-carboxy-
.alpha.-benzylsuccinic acid
NCI60_001739
d,l-benzylsuccinic acid
nsc20708 ,
884-33-3
OPREA1_299272
BIM-0015709.P001
dl-benzylsuccinic acid, >=99%
CHEMBL151284 ,
2-benzyl-succinic acid
AKOS001600536
bdbm50121929
36092-42-9
dl-benzylsuccinic acid
FT-0652906
HMS1608A16
A842582
2-benzylbutanedioic acid;2-benzylsuccinic acid
STK524740
butanedioic acid, (phenylmethyl)-
nsc 20708
CCG-103996
FT-0624377
FT-0611323
AM20060747
S6123
AB01317455-02
BBL028067
AKOS016038118
mono benzyl succinic acid
SY003042
(2r)-2-(phenylmethyl)butanedioic acid
SCHEMBL393002
2-benzylsuccinic acid #
mfcd00055798
CS-0037767
benzyl butanedioic acid
Q27098354
AS-10262
BCP12215
DTXSID90859847
NCGC00322037-01
alpha -benzylsuccinic acid
SB46650
butanedioic acid, (phenylmethyl)-, (a+/-)-
EN300-109182
HY-W044764
SY040253
Z1418939706
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
bacterial xenobiotic metaboliteAny bacterial metabolite produced by metabolism of a xenobiotic compound in bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
dicarboxylic acidAny carboxylic acid containing two carboxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carboxypeptidase A1Bos taurus (cattle)Ki0.50000.01000.17370.5000AID429443
Carboxypeptidase BHomo sapiens (human)Ki10.00001.10005.550010.0000AID429518
Mast cell carboxypeptidase AHomo sapiens (human)Ki0.45000.45000.45000.4500AID48493
Carboxypeptidase B2Homo sapiens (human)Ki0.45000.00400.22700.4500AID48493
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
leukotriene metabolic processCarboxypeptidase A1Bos taurus (cattle)
proteolysisCarboxypeptidase BHomo sapiens (human)
proteolysisCarboxypeptidase BHomo sapiens (human)
angiotensin maturationMast cell carboxypeptidase AHomo sapiens (human)
proteolysisMast cell carboxypeptidase AHomo sapiens (human)
positive regulation of extracellular matrix constituent secretionCarboxypeptidase B2Homo sapiens (human)
blood coagulationCarboxypeptidase B2Homo sapiens (human)
response to xenobiotic stimulusCarboxypeptidase B2Homo sapiens (human)
negative regulation of plasminogen activationCarboxypeptidase B2Homo sapiens (human)
protein catabolic processCarboxypeptidase B2Homo sapiens (human)
negative regulation of fibrinolysisCarboxypeptidase B2Homo sapiens (human)
cellular response to glucose stimulusCarboxypeptidase B2Homo sapiens (human)
liver regenerationCarboxypeptidase B2Homo sapiens (human)
negative regulation of hepatocyte proliferationCarboxypeptidase B2Homo sapiens (human)
proteolysisCarboxypeptidase B2Homo sapiens (human)
fibrinolysisCarboxypeptidase B2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
metallocarboxypeptidase activityCarboxypeptidase A1Bos taurus (cattle)
zinc ion bindingCarboxypeptidase A1Bos taurus (cattle)
carboxypeptidase activityCarboxypeptidase BHomo sapiens (human)
protein bindingCarboxypeptidase BHomo sapiens (human)
zinc ion bindingCarboxypeptidase BHomo sapiens (human)
metallocarboxypeptidase activityCarboxypeptidase BHomo sapiens (human)
metallocarboxypeptidase activityMast cell carboxypeptidase AHomo sapiens (human)
zinc ion bindingMast cell carboxypeptidase AHomo sapiens (human)
zinc ion bindingCarboxypeptidase B2Homo sapiens (human)
metallocarboxypeptidase activityCarboxypeptidase B2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
cytoplasmic vesicleCarboxypeptidase BHomo sapiens (human)
extracellular spaceCarboxypeptidase BHomo sapiens (human)
extracellular regionMast cell carboxypeptidase AHomo sapiens (human)
transport vesicleMast cell carboxypeptidase AHomo sapiens (human)
secretory granuleMast cell carboxypeptidase AHomo sapiens (human)
collagen-containing extracellular matrixMast cell carboxypeptidase AHomo sapiens (human)
extracellular spaceMast cell carboxypeptidase AHomo sapiens (human)
extracellular regionCarboxypeptidase B2Homo sapiens (human)
extracellular exosomeCarboxypeptidase B2Homo sapiens (human)
extracellular spaceCarboxypeptidase B2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID48477In vitro inhibition of Carboxypeptidase A (CPA) was determined by clot lysis assay using human plasma2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics.
AID48496In vitro inhibition of purified Carboxypeptidase B (CPB) by clot lysis assay in human plasma2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics.
AID48493The compound was evaluated for the inhibition of Carboxypeptidase A2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
2002 Alfred Burger Award Address in Medicinal Chemistry. Natural products and design: interrelated approaches in drug discovery.
AID89210Concentration of compound that gives 50% of the maximum acceleration of lysis was determined by clot lysis assay using human plasma2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics.
AID429443Inhibition of bovine carboxypeptidase A12009European journal of medicinal chemistry, Aug, Volume: 44, Issue:8
A new type of five-membered heterocyclic inhibitors of basic metallocarboxypeptidases.
AID48647In vitro inhibition of purified Carboxypeptidase M (CPM) by clot lysis assay in human plasma2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics.
AID89377In vitro inhibition of thrombin-activatable fibrinolysis was determined by clot lysis assay using human plasma2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics.
AID429442Inhibition of corn earworm recombinant carboxypeptidase B expressed in Pichia pastoris system2009European journal of medicinal chemistry, Aug, Volume: 44, Issue:8
A new type of five-membered heterocyclic inhibitors of basic metallocarboxypeptidases.
AID48648In vitro inhibition of purified Carboxypeptidase N (CPN) by clot lysis assay in human plasma2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics.
AID429518Inhibition of human recombinant carboxypeptidase B expressed in Pichia pastoris system2009European journal of medicinal chemistry, Aug, Volume: 44, Issue:8
A new type of five-membered heterocyclic inhibitors of basic metallocarboxypeptidases.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (20.83)18.7374
1990's6 (25.00)18.2507
2000's7 (29.17)29.6817
2010's6 (25.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.59 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index4.50 (4.65)
Search Engine Demand Index26.69 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (4.00%)4.05%
Observational0 (0.00%)0.25%
Other24 (96.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]